The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Construction is now underway with the facility scheduled to be operational by 2025
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Rabies claims around 59,000 deaths globally a year, of which around 20,000 or just over one-third of the deaths take place in India alone
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
Subscribe To Our Newsletter & Stay Updated
